Mankind Pharma IPO GMP, Review, Price, Allotment

3

Last updated on November 27, 2023

Mankind Pharma IPO GMP 2023

Mankind Pharma IPO description – Mankind Pharma is India’s fourth-largest pharmaceutical company in terms of domestic sales and second-largest in terms of sales volume in FY 2022. The company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

The company is focused on the domestic market which contributed 97.6% of its total revenue from operations for FY 2022. Mankind Pharma has created 36 brands in its pharmaceutical business that have each achieved over INR 50 crore in domestic sales in FY 2022. The company is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.

As of 31 March 2022, Mankind Pharma operated 23 manufacturing facilities across India and had 2,181 manufacturing personnel. Its formulations manufacturing facilities have a total installed capacity of 40.77 billion units across a wide range of dosage forms including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives, other over-the-counter products. The company had a team of over 600 scientists and dedicated in-house R&D center at IMT Manesar, Haryana.

Mankind Pharma 2023

Promoters of Mankind Pharma – Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja


Mankind Pharma IPO Details

Mankind Pharma IPO Dates25 – 27 April 2023
Mankind Pharma IPO PriceINR 1,026 – 1,080 per share
Fresh issueNil
Offer For Sale4,00,58,844 shares (INR 4,110.04 – 4,326.36 crore)
Total IPO sizeINR 4,326.36 crore
Minimum bid (lot size)13 shares (INR 14,040)
Face Value INR 1 per share
Retail Allocation35%
Listing OnBSE, NSE

Mankind Pharma Financial Performance

 FY 2020FY 2021FY 20229M FY 2023
Revenue5,865.26,214.47,781.66,696.8
Expenses4,549.54,705.56,017.45,493.5
Net income1,056.21,293.01,453.01,010.2
PAT Margin (%)18.020.818.715.1
Figures in INR Crores unless specified otherwise

Mankind Pharma Offer News


Mankind Pharma Valuations & Margins

FY 2020FY 2021FY 2022
EPS25.7231.5935.78
PE ratio28.68 – 30.18
RONW (%)29.5626.8023.29
NAV153.65
ROCE (%)35.8630.4125.50
EBITDA (%)24.6926.7125.75
Debt/Equity(0.03)0.020.08
*Compiled by IPO Central from Prospectus

Mankind Pharma IPO GMP Today

DateConsolidated IPO GMPKostakSubject to Sauda
8 May 202390850
6 May 202385700
5 May 202385600
4 May 202380600800
3 May 202370500600
2 May 202375500650
29 Apr 202370500600
28 Apr 202355450550
27 Apr 202345400500
26 Apr 202370550600
25 Apr 202385650750
24 Apr 202375500700
21 Apr 202380500750
20 Apr 202380500750
19 Apr 202390550800
18 Apr 202380500700
17 Apr 202390550800
15 Apr 2023100600850

Mankind Pharma IPO Subscription – Live Updates

CategoryQIBNIIRetailTotal
Shares Offered80,11,76960,08,8271,40,20,5962,80,41,192
27 Apr 202349.163.800.9215.32
26 Apr 20231.861.020.250.87
25 Apr 20230.070.330.110.14

Mankind Pharma IPO Reviews – Subscribe or Avoid?

Aditya Birla Capital – Subscribe
Angel One –
Anand Rathi –
Antique Stock Broking –
Arihant Capital –
Ashika Research – Compelling Investment Opportunity
Asit C Mehta – Subscribe
BP Wealth – Avoid
Canara Bank Securities – Subscribe
Centrum Broking – Subscribe
Choice Broking – Subscribe
Dalal & Broacha –
Elite Wealth – Subscribe for Long-Term
Geojit – Subscribe
GEPL Capital – Subscribe
Hem Securities – Long-Term Subscribe
ICICIdirect – Subscribe
Jainam Broking –
KR Choksey –
LKP Research –
Marwadi Financial – Subscribe
Motilal Oswal –
Nirmal Bang –
Reliance Securities –
Religare Broking –
Samco Securities – Avoid
SBI Capital – Subscribe
SMC Global – 2/5
Swastika Investmart – Subscribe
Ventura Securities –


Mankind Pharma Offer Registrar

KFIN TECHNOLOGIES LIMITED
Selenium Tower – B, Plot 31 & 32, Gachibowli,
Financial District, Nanakramguda, Serilingampally,
Hyderabad – 500 032, Telangana
Telephone: +91 40 6716 2222
Email: [email protected]
Website: www.kfintech.com


Mankind Pharma Contact Details

MANKIND PHARMA LIMITED
262, Okhla Industrial Estate, Phase-III,
New Delhi 110 020, Delhi, India
Phone: +91 11 4684 6729
E-mail: [email protected]
Website: www.mankindpharma.com


Mankind Pharma IPO Allotment Status

Mankind Pharma IPO allotment status is now available on the KFin Tech website. Click on this link to get allotment status.


Mankind Pharma IPO Dates & Listing Performance

Mankind Pharma IPO Opening Date25 April 2023
Mankind Pharma IPO Closing Date27 April 2023
Finalization of Basis of Allotment3 May 2023
Initiation of refunds4 May 2023
Transfer of shares to demat accounts8 May 2023
Mankind Pharma Listing Date9 May 2023
Opening Price on NSE SMEINR 1,300 per share (up 20.37%)
Closing Price on NSE SMEINR 1,422.3 per share (up 31.7%)

Read Also: Nifty Pharma Stocks List With Weightage in 2023

Mankind Pharma IPO FAQs

How many shares in Mankind Pharma IPO are reserved for HNIs and retail investors?

The investors’ portion for QIB – 50%, NII – 15%, and Retail – 35%.

How to apply for Mankind Pharma Public Offer?

The best way to apply for Mankind Pharma public offer is through Internet banking ASBA (know all about ASBA here). You can also apply online through your stock broker using UPI. If you prefer to make paper applications, fill up an offline IPO form and deposit the same to your broker.

What is Mankind Pharma IPO GMP today?

Mankind Pharma IPO GMP today is INR 90 per share.

What is Mankind Pharma’s kostak rate today?

Mankind Pharma kostak rate today is INR 850 per application.

What is Mankind Pharma Subject to Sauda rate today?

Mankind Pharma Subject to Sauda rate today is NA per application.

3 COMMENTS

  1. IPO is overpriced and sentiments are not good currently. GMP is declining due various reasons so not good time for investment. Who knows what will be premium at the time of listing it could be negative too.

LEAVE A REPLY

Please enter your comment!
Please enter your name here